Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
1.390
+0.100 (7.75%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neuronetics Employees
Neuronetics had 203 employees as of December 31, 2023. The number of employees increased by 9 or 4.64% compared to the previous year.
Employees
203
Change (1Y)
9
Growth (1Y)
4.64%
Revenue / Employee
$358,182
Profits / Employee
-$179,424
Market Cap
42.18M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Achilles Therapeutics | 215 |
Passage Bio | 58 |
AN2 Therapeutics | 41 |
SCYNEXIS | 29 |
Aileron Therapeutics | 15 |
CalciMedica | 12 |
Lexaria Bioscience | 7 |
Nexalin Technology | 6 |
STIM News
- 3 days ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Neuronetics and Greenbrook TMS Announce Closing of Transaction - GlobeNewsWire
- 4 weeks ago - Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results - GlobeNewsWire
- 5 weeks ago - Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results - GlobeNewsWire
- 7 weeks ago - Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call - GlobeNewsWire
- 2 months ago - NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression - GlobeNewsWire